ストックスクリーナーアプリを入手
1.56
5.71%
-0.105
Inmune Bio Inc (INMB) 最新ニュース
INmune Bio Inc. Announces Warrant Inducement Offer and Amendment to April 2024 Warrants – Key Details from Latest 8-K Filing – Minichart - Minichart
INmune Bio Executes Warrant Inducement and Extension Agreement - TipRanks
INMB Seeks Patent Approval for CORDStrom Platform - GuruFocus
INmune Bio files U.S. patent for cell therapy platform - Investing.com
Inmune Bio Raises ~$0.9M Via $1.40 Warrant Inducement, Extends Remaining Warrants to 2027 - TradingView
INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry - Stock Titan
INmune Bio files U.S. patent for cell therapy platform By Investing.com - Investing.com Canada
INmune Bio moves CORDStrom into U.S. patent review - Stock Titan
Price to sales forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
Price to earnings forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc.(NasdaqCM:INMB) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Dynamic Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBIT forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000E Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc (INMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INmune Bio, Inc. Actuals & Estimates (NASDAQ:INMB) - TradingView
INMB Forecast — Price Target — Prediction for 2027 - TradingView
INMB Secures UK Regulatory Approval for Pediatric Treatment Plan - GuruFocus
INmune Bio receives UK regulatory approval for RDEB treatment plan - Investing.com
INmune Bio receives UK regulatory approval for RDEB treatment plan By Investing.com - Investing.com Canada
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™ - The Manila Times
INmune Bio clears key UK pediatric review for Ebstrocel in RDEB - Stock Titan
INmune Bio Inc (INMB) Institutional Confidence - TradingKey
INmune Bio Advances Ebstrocel Toward UK Conditional Approval - TipRanks
MHRA backs INmune Bio (NASDAQ: INMB) plan for 2026 UK CORDStrom filing - Stock Titan
INMB Receives Regulatory Guidance for CORDStrom in Epidermolysis Bullosa - GuruFocus
INmune Bio receives MHRA alignment for RDEB therapy filing - Investing.com
INmune Bio's CORDStrom Gets Written Alignment on UK Conditional Marketing Authorization Application - marketscreener.com
INmune Bio receives MHRA alignment for RDEB therapy filing By Investing.com - Investing.com India
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB - The Manila Times
INmune Bio wins MHRA backing for 2026 UK rare-disease filing - Stock Titan
INmune Bio Inc (INMB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inmune Bio focuses on Alzheimer’s data, shares on NASDAQ in a volatile biotech niche - AD HOC NEWS
INmune Bio and Anthony Nolan Expand Collaboration to Secure Umbilical Cord Tissue Supply for CORDStrom™ Cell Therapy Platform - BioInformant
INmune Bio Inc (INMB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
INmune Bio Inc (INMB) Valuation: PE, PB & Fair Value Analysis - TradingKey
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio Inc (INMB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INmune Bio Inc (INMB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
INmune Bio Inc (INMB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inmune Bio Shareholders Reaffirm Board, Auditor and Incentive Plan - TipRanks
INmune Bio (INMB) holders OK larger stock plan and evergreen share increases - Stock Titan
INMB Q4 2025 Earnings: EPS Surprise of 24.6% Highlights Operational ProgressNon-GAAP Earnings - newsline.com
INMB Q4 2025 Earnings: EPS Beat Surprises Street as Clinical Pipeline AdvancesTax Rate Impact - newsline.com
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $8 - Moomoo
INmune Bio reports positive Phase 2 MRI results - TipRanks
New MRI biomarker backs INmune Bio (NASDAQ: INMB) Alzheimer’s drug - Stock Titan
INMB: INmune Bio Reports Promising MRI Findings from Alzheimer's Trial - GuruFocus
INmune Bio Reports Statistically Significant Treatment Effect On Advanced White Matter MRI Biomarker In Phase 2 MINDFuL Alzheimer's Trial - marketscreener.com
INmune Bio reports positive MRI results from Alzheimer’s trial - Investing.com
INmune Bio Reports Statistically Significant Treatment Effect On Advanced White Matter MRI Biomarker In Phase 2 Mindful Alzheimer's Trial - TradingView
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial - The Manila Times
Brain scans in early Alzheimer’s trial show drug affecting white matter - Stock Titan
INmune Bio (INMB) Q4 2025 Earnings Transcript - The Globe and Mail
INmune Bio (INMB) Holds Near Support Amid Modest Decline – Key Levels in FocusAAII Bearish - newsline.com
Inmune Bio Inc stock (US45764T1060): Short interest rose in May - AD HOC NEWS
INMB Q4 2025 Earnings: EPS Beat Surprises as Clinical-Stage Biotech Advances PipelineConsensus Miss Rate - The Legal Advocate
1.16%
0.48%
大文字化:
|
ボリューム (24 時間):